Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-05544-w, published online 31 January 2022
The original version of this Article contained errors.
In the Abstract,
“In the high-dose (5 mg/ml) clinical study, AR68 was given once per week for 24 weeks and showed 83% efficacy in increasing hair counts compared with finasteride.”
Now reads:
“In the 24-week long high-dose (5 mg/ml) clinical study, AR68 showed average additional hair growth of 1.3–1.9 hairs/cm2 per month, which is comparable to finasteride.”
In the Discussion section,
“In comparison with the clinical trial of daily oral administration of 1 mg finasteride for a 24-week period45,46,47, high-dose AR68 treatment per week caused 83% improvement in hair loss. Although the efficacy did not reach that of finasteride, AR68 has no adverse effects and is more convenient as a weekly treatment. This study has limitations in a number of subjects and a spectrum of races. For further studies, we will test lower frequencies treatment through clinical studies with more subjects to determine the best dose and frequency. In further studies, we will analyze androgen levels in FPHL to determine the relationship between the efficacy of AR68 and androgen levels. We also plan to perform a clinical study with Caucasian subjects with a higher AGA incidence.”
Now reads:
“In comparison to the ~9.3 hairs/cm2 average hair growth seen with daily oral administration of 1 mg finasteride over a 24-week period45,46,47, high-dose AR68 treatment per week over 16-week period led to average hair growth of 7.5 hairs/cm2, indicating comparable efficacy as finasteride. AR68 has no adverse effects and is more convenient as a weekly treatment. This study has limitations in a number of subjects and a spectrum of races. We plan to perform a clinical study with Caucasian subjects with a higher AGA incidence.”
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yun, SI., Lee, SK., Goh, EA. et al. Author Correction: Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep 12, 5675 (2022). https://doi.org/10.1038/s41598-022-10024-2
Published:
DOI: https://doi.org/10.1038/s41598-022-10024-2
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
